NR2F6 and neoplasm: This suggests that targeting the immune checkpoint NR2F6 in those presumably tumor antigen-reactive but probably exhausted T-cell clones in the patient group with NR2F6positive TILs may result in increased anti-tumor effector responses during an envisioned NR2F6-targeted therapy.